Quantitative analysis for Grifols, S.A. (GRFS) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (43.0) (grade D). 30 signals analyzed (26 differentiated alt-data).
GRFS stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $8.07 | $7.87 | $7.91 |
| 2026-05-11 | $8.08 | $7.73 | $7.80 |
| 2026-05-21 | $8.16 | $8.07 | $8.11 |
| 2026-06-03 | $7.60 | $7.43 | $7.47 |
| 2026-06-15 | $7.73 | $7.61 | $7.62 |
| 2026-06-26 | $7.49 | $7.36 | $7.39 |
| 2026-07-09 | $7.31 | $7.17 | $7.29 |
| 2026-07-21 | $7.75 | $7.59 | $7.75 |
| 2026-07-31 | $7.98 | $7.71 | $7.87 |
| 2026-08-12 | $7.98 | $7.89 | $7.93 |
| 2026-08-24 | $8.03 | $7.94 | $7.99 |
| 2026-09-03 | $7.99 | $7.81 | $7.88 |
How Grifols, S.A. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| CNTA | Centessa Pharmaceuticals plc | $6.2B | — |
| ABVX | Abivax S.A. | $7.9B | — |
| BLCO | Bausch + Lomb Corporation | $5.8B | — |
| BLTE | Belite Bio, Inc | $5.7B | — |
View all Health Care stocks by valuation and signals →
Grifols, S.A. (GRFS) scores Sell (43.0), and the composite conceals a 56-point disagreement between its dimensions. It is strongest on valuation at 78, and weakest on technicals at 23 and analyst consensus at 22. A stock can carry valuation that high while analyst consensus sits at 22; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| valuation | 78 |
| technicals | 23 |
| analyst consensus | 22 |
StoQuant analyzes 30 signals (26 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Grifols, S.A. (GRFS): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/GRFS"><img src="https://stoquant.com/badge/GRFS.svg" alt="Grifols, S.A. (GRFS) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.